Skip to main content
NCBI home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1980 Feb;65(2):347–356. doi: 10.1172/JCI109678

Urinary Kallikrein Excretion in Essential and Mineralocorticoid Hypertension

O Bryan Holland 1, James M Chud 1, Helen Braunstein 1
PMCID: PMC371373  PMID: 7356684

Abstract

Urinary kallikrein excretion has been reported to be decreased in patients with essential hypertension and elevated in patients with primary aldosteronism as a reflection of mineralocorticoid activity. Low renin essential hypertension (LREH) has been postulated to result from excess production of an unknown mineralocorticoid(s). Urinary kallikrein excretion was compared in outpatients with essential hypertension, mineralocorticoid hypertension (primary aldosteronism and 17α-hydroxylase deficiency), and in normal subjects of the same race. No significant difference in urinary kallikrein excretion of patients with LREH vs. normal renin essential hypertension (NREH) was found for either black (4.1±0.4 vs. 4.8±0.5 esterase units (EU)/24 h, mean±SE, for 27 LREH and 38 NREH, respectively) or white patients (12.2±2.3 vs. 11.7±1.4 EU/24 h for 13 LREH and 25 NREH, respectively). Urinary kallikrein was decreased in black vs. white hypertensive patients and normal subjects. However, in patients with normal renal function (creatinine clearance ≥80 ml/min) urinary kallikrein was not significantly decreased in either black hypertensive vs. black normal subjects (4.3±0.3 vs. 5.4±0.6 EU/24 h) or in white hypertensive vs. white normal subjects (11.9±1.2 vs. 8.4±0.9 EU/24 h). In contrast, hypertensive patients with mild renal insufficiency (creatinine clearance of 41.8±78.5 ml/min) had reduced (P < 0.05) urinary kallikrein (3.3 EU/24 h with creatinine clearance of 63.6±2.0 for 24 black patients and 4.2±0.7 EU/24 h with creatinine clearance of 67.0±3.5 for 6 white patients). These results suggest that a reduction in urinary kallikrein excretion rate is an early accompaniment of hypertensive renal injury. Urinary kallikrein excretion in response to a 6-d 10-meq sodium diet and a 3-d Florinef (0.5 mg b.i.d.) administration was compared in hypertensive patients with normal renal function vs. race and age-matched normal subjects. Stimulation of urinary kallikrein excretion by Florinef was equal in black and white normal subjects vs. hypertensive patients (black normals = 12.3±2.7 [n = 9], NREH = 11.7±1.8 [n = 10], LREH = 10.9±1.5 [n = 12]; white normals = 21.2±2.9 [n = 11], essential hypertension = 20.9±3.2 [10 NREH, 5 LREH]). Stimulation of urinary kallikrein excretion with low sodium diet was decreased (P < 0.05) only in black LREH (black normals = 11.2±2.4 [n = 10], NREH = 10.1±2.7 [n = 10], LREH = 7.4±1.1 [n = 13]; white normals = 19.1±2.7 [n = 13], essential hypertension = 17.5±2.3 [nine NREH, four LREH]). However, during low sodium diet, black patients with LREH had evidence for less sodium depletion as manifested by a decreased rise in urinary aldosterone excretion (16.3±2.7 vs. 33.3±6.4 μg/24 h for black normals) and a failure to achieve metabolic balance in 11/13 patients. Thus, the lesser kallikrein stimulation appeared to result from these two factors. Black and white hypertensives with creatinine clearance <80 ml/min had little increase in urinary kallikrein excretion with Florinef or low sodium diet.

5 of 12 patients with primary aldosteronism or 17α-hydroxylase deficiency did not have an elevated urinary kallikrein excretion rate. Mild renal insufficiency may have contributed to this finding in two of these five patients. Nevertheless, this finding illustrates a limitation to the use of urinary kallikrein excretion rate as an index of mineralocorticoid activity. However, it appears that the majority of patients with LREH have no evidence for excess production of an unknown mineralocorticoid. The failure to find a decrease in urinary kallikrein excretion in racially matched patients with essentil hypertension and normal renal function questions the postulate of a role of the kallikrein-kinin system in the initiation of essential hypertension.

Full text

PDF
347

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Adetuyibi A., Mills I. H. Relation between urinary kallikrein and renal function, hypertension, and excretion of sodium and water in man. Lancet. 1972 Jul 29;2(7770):203–207. doi: 10.1016/s0140-6736(72)91636-4. [DOI] [PubMed] [Google Scholar]
  2. Biglieri E. G., Herron M. A., Brust N. 17-hydroxylation deficiency in man. J Clin Invest. 1966 Dec;45(12):1946–1954. doi: 10.1172/JCI105499. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. DAVIES D. F., SHOCK N. W. Age changes in glomerular filtration rate, effective renal plasma flow, and tubular excretory capacity in adult males. J Clin Invest. 1950 May;29(5):496–507. doi: 10.1172/JCI102286. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Geller R. G., Margolius H. S., Pisano J. J., Keiser H. R. Effects of mineralocorticoids, altered sodium intake, and adrenalectomy on urinary kallikrein in rats. Circ Res. 1972 Dec;31(6):857–861. doi: 10.1161/01.res.31.6.857. [DOI] [PubMed] [Google Scholar]
  5. Glasser R. J., Michael A. F. Urinary kallikrein in experimental renal disease. Lab Invest. 1976 Jun;34(6):616–622. [PubMed] [Google Scholar]
  6. Goldring W., Chasis H., Ranges H. A., Smith H. W. EFFECTIVE RENAL BLOOD FLOW IN SUBJECTS WITH ESSENTIAL HYPERTENSION. J Clin Invest. 1941 Nov;20(6):637–653. doi: 10.1172/JCI101257. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Gomez-Sanchez C., Kem D. C., Kaplan N. M. A radioimmunoassay for plasma aldosterone by immunologic purification. J Clin Endocrinol Metab. 1973 Apr;36(4):795–798. doi: 10.1210/jcem-36-4-795. [DOI] [PubMed] [Google Scholar]
  8. Greco A. V., Porcelli G., Croxatio H. R., Fedeli G., Ghirlanda G. Ipertensione arteriosa e callicreina urinaria. Minerva Med. 1974 Aug 18;65(58):3058–3062. [PubMed] [Google Scholar]
  9. Haber E., Koerner T., Page L. B., Kliman B., Purnode A. Application of a radioimmunoassay for angiotensin I to the physiologic measurements of plasma renin activity in normal human subjects. J Clin Endocrinol Metab. 1969 Oct;29(10):1349–1355. doi: 10.1210/jcem-29-10-1349. [DOI] [PubMed] [Google Scholar]
  10. Horwitz D., Margolius H. S., Keiser H. R. Effects of dietary potassium and race on urinary excretion of kallikrein and aldosterone in man. J Clin Endocrinol Metab. 1978 Aug;47(2):296–299. doi: 10.1210/jcem-47-2-296. [DOI] [PubMed] [Google Scholar]
  11. Hunt T. K., Schambelan M., Biglieri E. G. Selection of patients and operative approach in primary aldosteronism. Ann Surg. 1975 Oct;182(4):353–361. doi: 10.1097/00000658-197510000-00001. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Kem D. C., Weinberger M. H., Mayes D. M., Nugent C. A. Saline suppression of plasma aldosterone in hypertension. Arch Intern Med. 1971 Sep;128(3):380–386. [PubMed] [Google Scholar]
  13. Langan J., Jackson R., Adlin E. V., Channick B. J. A simple radioimmunoassay for urinary aldosterone. J Clin Endocrinol Metab. 1974 Feb;38(2):189–193. doi: 10.1210/jcem-38-2-189. [DOI] [PubMed] [Google Scholar]
  14. Lawton W. J., Fitz A. E. Urinary kallikrein in normal renin essential hypertension. Circulation. 1977 Nov;56(5):856–859. doi: 10.1161/01.cir.56.5.856. [DOI] [PubMed] [Google Scholar]
  15. Lechi A., Covi G., Lechi C., Corgnati A., Arosio E., Zatti M., Scuro L. A. Urinary kallikrein excretion and plasma renin activity in patients with essential hypertension and primary aldosteronism. Clin Sci Mol Med. 1978 Jul;55(1):51–55. doi: 10.1042/cs0550051. [DOI] [PubMed] [Google Scholar]
  16. Lechi C., Rasi G. P., Covi G., Arosio E., Zannini G., Lechi A. Urinary and kidney kallikrein in hypertensive rats. Biomedicine. 1976 Sep 30;25(7):236–238. [PubMed] [Google Scholar]
  17. Levinsky N. G. The renal kallikrein-kinin system. Circ Res. 1979 Apr;44(4):441–451. doi: 10.1161/01.res.44.4.441. [DOI] [PubMed] [Google Scholar]
  18. Levy S. B., Frigon R. P., Stone R. A. The relationship of urinary kallikrein activity to renal salt and water excretion. Clin Sci Mol Med. 1978 Jan;54(1):39–45. doi: 10.1042/cs0540039. [DOI] [PubMed] [Google Scholar]
  19. Levy S. B., Lilley J. J., Frigon R. P., Stone R. A. Urinary kallikrein and plasma renin activity as determinants of renal blood flow. The influence of race and dietary sodium intake. J Clin Invest. 1977 Jul;60(1):129–138. doi: 10.1172/JCI108749. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Liddle G. W., Hollifield J. W., Slaton P. E., Wilson H. M. Effects of various adrenal inhibitors in low-renin essential hypertension. J Steroid Biochem. 1976 Nov-Dec;7(11-12):937–940. doi: 10.1016/0022-4731(76)90015-7. [DOI] [PubMed] [Google Scholar]
  21. Luft F. C., Grim C. E., Willis L. R., Higgins J. T., Jr, Weinberger M. H. Natriuretic response to saline infusion in normotensive and hypertensive man. The role of renin suppression in exaggerated natriuresis. Circulation. 1977 May;55(5):779–784. doi: 10.1161/01.cir.55.5.779. [DOI] [PubMed] [Google Scholar]
  22. MILLER J. H., SHOCK N. W. Age differences in the renal tubular response to antidiuretic hormone. J Gerontol. 1953 Oct;8(4):446–450. doi: 10.1093/geronj/8.4.446. [DOI] [PubMed] [Google Scholar]
  23. Margolis H. S., Geller R., Pisano J. J., Sjoerdsma A. Altered urinary kallikrein excretion in human hypertension. Lancet. 1971 Nov 13;2(7733):1063–1065. doi: 10.1016/s0140-6736(71)90382-5. [DOI] [PubMed] [Google Scholar]
  24. Margolius H. S., Chao J., Kaizu T. The effects of aldosterone and spironolactone on renal kallikrein in the rat. Clin Sci Mol Med Suppl. 1976 Dec;3:279s–282s. doi: 10.1042/cs051279s. [DOI] [PubMed] [Google Scholar]
  25. Margolius H. S., Geller R., De Jong W., Pisano J. J., Sjoerdsma A. Altered urinary kallikrein excretion in rats with hypertension. Circ Res. 1972 Mar;30(3):358–362. [PubMed] [Google Scholar]
  26. Margolius H. S., Horwitz D., Geller R. G., Alexander R. W., Gill J. R., Jr, Pisano J. J., Keiser H. R. Urinary kallikrein excretion in normal man. Relationships to sodium intake and sodium-retaining steroids. Circ Res. 1974 Dec;35(6):812–819. doi: 10.1161/01.res.35.6.812. [DOI] [PubMed] [Google Scholar]
  27. Margolius H. S., Horwitz D., Pisano J. J., Keiser H. R. Urinary kallikrein excretion in hypertensive man. Relationships to sodium intake and sodium-retaining steroids. Circ Res. 1974 Dec;35(6):820–825. doi: 10.1161/01.res.35.6.820. [DOI] [PubMed] [Google Scholar]
  28. Mersey J. H., Williams G. H., Emanuel R., Dluhy R. G., Wong P. Y., Moore T. J. Plasma bradykinin levels and urinary kallikrein excretion in normal renin essential hypertension. J Clin Endocrinol Metab. 1979 Apr;48(4):642–647. doi: 10.1210/jcem-48-4-642. [DOI] [PubMed] [Google Scholar]
  29. Mitas J. A., Levy S. B., Holle R., Frigon R. P., Stone R. A. Urinary kallikrein activity in the hypertension of renal parenchymal disease. N Engl J Med. 1978 Jul 27;299(4):162–165. doi: 10.1056/NEJM197807272990402. [DOI] [PubMed] [Google Scholar]
  30. Seino M., Abe K., Otsuka Y., Saito T., Irokawa N. Urinary kallikrein excretion and sodium metabolism in hypertensive patients. Tohoku J Exp Med. 1975 Aug;116(4):359–367. doi: 10.1620/tjem.116.359. [DOI] [PubMed] [Google Scholar]
  31. Seino M., Abe K., Sakurai Y., Irokawa N., Yasujima M., Chiba S., Otsuka Y., Yoshinaga K. Effect of spironolactone on urinary kallikrein excretion in patients with essential hypertension and in primary aldosteronism. Tohoku J Exp Med. 1977 Feb;121(2):111–119. doi: 10.1620/tjem.121.111. [DOI] [PubMed] [Google Scholar]
  32. Sennett J. A., Brown R. D., Island D. P., Yarbro L. R., Watson J. T., Slaton P. E., Hollifield J. W., Liddle G. W. Evidence for a new mineralocorticoid in patients with low-renin essential hypertension. Circ Res. 1975 Jun;36(6 Suppl 1):2–9. doi: 10.1161/01.res.36.6.2. [DOI] [PubMed] [Google Scholar]
  33. Ward P. E., Gedney C. D., Dowben R. M., Erdös E. G. Isolation of membrane-bound renal kallikrein and kininase. Biochem J. 1975 Dec;151(3):755–758. doi: 10.1042/bj1510755. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES